Eman Refaat Youness
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eman Refaat Youness has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Omar Mohamed E. Abdel Salam
Department of Toxicology and Narcotics, Medical Research and Clinical Studies Institute, National Research Centre, Dokki, Cairo, Egypt
17 shared publications - Moushira Erfan Zaki
Biological Anthropology Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt
12 shared publications - Amany Ameen Sleem
Pharmacology Department, National Research Centre, Dokki, Giza, Egypt
11 shared publications - Enayat A. Omara
National Research Centre
7 shared publications - Hala Tabie El-Bassyouni
Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
7 shared publications - Yasser Ashry Khadrawy
Medical Physiology Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt
7 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 3 (19) , 2292-2299
Association of Serum TNF-α and HSP-70 with Serologic and Cutaneous Manifestations in Pediatric Celiac Disease
Celiac disease is a gluten-triggered chronic autoimmune disorder occurring in genetically susceptible individuals. Several inflammatory cytokines, including tumor necrosis factor (TNF-α), showed elevated levels, contributing to CD pathogenesis and its aggravation. Heat shock protein -70 (HSP-70) is stress-induced chaperones that protect cells against injurious extracellular factors and have emerged as drug targets for autoimmune syndromes. We aimed to examine the role of TNF-α and HSPs in the pathophysiology of CD. Thirty-five children with celiac disease (22 females and 13 males) and 40 healthy controls matching age and sex were included in this case-control study. Using commercially available kits, serum anti-tissue transglutaminase antibodies, TNF-α, and HSP-70 were measured by ELISA, and HPLC measured total IgA. The mean patients’ age at diagnosis was (5 ± 3.11) years. They mainly presented with gastrointestinal symptoms. The mean serum levels of TNF-α (157.36±18.87 pg/ml) and Heat shock protein—70 (113.34±18.77 ng/ml) were significantly increased (p= 0.001) in children with celiac disease compared to healthy controls (101.11±15.39, 62.79± 21.31) respectively. A significant positive correlation between TNF-α, HSP-70, and anti-tissue transglutaminase antibodies was delineated in children with celiac disease. Skin manifestations were present in 34.3% of CD patients. Despite the relatively small sample size, this study elucidates the association of elevated TNF-alpha and HSP-70 with celiac disease in children. Additionally, the present results elucidated the association between CD and skin manifestations.
- 30 September 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 3 (19) , 2292-2299
Open AccessAssociation of Serum TNF-α and HSP-70 with Serologic and Cutaneous Manifestations in Pediatric Celiac Disease
Celiac disease is a gluten-triggered chronic autoimmune disorder occurring in genetically susceptible individuals. Several inflammatory cytokines, including tumor necrosis factor (TNF-α), showed elevated levels, contributing to CD pathogenesis and its aggravation. Heat shock protein -70 (HSP-70) is stress-induced chaperones that protect cells against injurious extracellular factors and have emerged as drug targets for autoimmune syndromes. We aimed to examine the role of TNF-α and HSPs in the pathophysiology of CD. Thirty-five children with celiac disease (22 females and 13 males) and 40 healthy controls matching age and sex were included in this case-control study. Using commercially available kits, serum anti-tissue transglutaminase antibodies, TNF-α, and HSP-70 were measured by ELISA, and HPLC measured total IgA. The mean patients’ age at diagnosis was (5 ± 3.11) years. They mainly presented with gastrointestinal symptoms. The mean serum levels of TNF-α (157.36±18.87 pg/ml) and Heat shock protein—70 (113.34±18.77 ng/ml) were significantly increased (p= 0.001) in children with celiac disease compared to healthy controls (101.11±15.39, 62.79± 21.31) respectively. A significant positive correlation between TNF-α, HSP-70, and anti-tissue transglutaminase antibodies was delineated in children with celiac disease. Skin manifestations were present in 34.3% of CD patients. Despite the relatively small sample size, this study elucidates the association of elevated TNF-alpha and HSP-70 with celiac disease in children. Additionally, the present results elucidated the association between CD and skin manifestations.
- Open Access
- 25 June 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 2 (19) , 1853-1864
Prevalence of Helicobacter pylori Infection in a sample of Egyptian Children with Refractory Iron Deficiency Anemia
Helicobacter pylori(H. pylori) infection has been implicated in refractory iron deficiency anemia (IDA) in children, raising concern due to its potential impact on growth and development. We aimed to determine the occurrence of H. pylori infection in children with IDA, its association with refractoriness to oral iron therapy, and its impact on growth.100 children participated in this cross-sectional study aged 4–12 years with IDA who failed to respond to 6 weeks of therapeutic iron supplementation. Participants, recruited from El Galaa Teaching Hospital, underwent full clinical assessment, anthropometry, and laboratory evaluation for IDA indices, H. pylori infection liver and kidney functions.H. pylori infection was detected in 77% of patients. Children who were infected had much lower BMI Z-scores, hematocrit (P = 0.001), hemoglobin (P < 0.001), serum iron (P < 0.001), and ferritin (P = 0.003), and significantly higher TIBC (P < 0.001) than uninfected children. H. pylori infection correlated negatively with BMI Z-score, Hb, Ht, MCV, serum iron, and ferritin (P < 0.05), and positively with TIBC (P < 0.001). Z-scores for height and weight showed no discernible variations.H. pylori infection is strongly relatedto refractory IDA and should be investigated in all affected cases. Although no association with linear growth was observed, H. pylori was negatively linked with nutritional status, reflected by lower BMI Z-scores.
- 25 June 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 2 (19) , 1853-1864
Open AccessPrevalence of Helicobacter pylori Infection in a sample of Egyptian Children with Refractory Iron Deficiency Anemia
Helicobacter pylori(H. pylori) infection has been implicated in refractory iron deficiency anemia (IDA) in children, raising concern due to its potential impact on growth and development. We aimed to determine the occurrence of H. pylori infection in children with IDA, its association with refractoriness to oral iron therapy, and its impact on growth.100 children participated in this cross-sectional study aged 4–12 years with IDA who failed to respond to 6 weeks of therapeutic iron supplementation. Participants, recruited from El Galaa Teaching Hospital, underwent full clinical assessment, anthropometry, and laboratory evaluation for IDA indices, H. pylori infection liver and kidney functions.H. pylori infection was detected in 77% of patients. Children who were infected had much lower BMI Z-scores, hematocrit (P = 0.001), hemoglobin (P < 0.001), serum iron (P < 0.001), and ferritin (P = 0.003), and significantly higher TIBC (P < 0.001) than uninfected children. H. pylori infection correlated negatively with BMI Z-score, Hb, Ht, MCV, serum iron, and ferritin (P < 0.05), and positively with TIBC (P < 0.001). Z-scores for height and weight showed no discernible variations.H. pylori infection is strongly relatedto refractory IDA and should be investigated in all affected cases. Although no association with linear growth was observed, H. pylori was negatively linked with nutritional status, reflected by lower BMI Z-scores.
- Open Access
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 719-737
Effect of Ramadan Fasting on Chronic Kidney Disease Patients
This prospective cohort study evaluated the impact of Ramadan fasting on 162 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) on regular hemodialysis. Participants were categorized based on fasting behavior and renal status. Biochemical and clinical parameters were assessed before, during, and after Ramadan. Results indicated that fasting was generally well-tolerated, though significant transient increases in blood urea, potassium, and phosphate were observed during fasting periods, particularly among ESRD patients fasting on dialysis days. Serum sodium and eGFR showed significant declines over time in both fasting and non-fasting CKD groups. No adverse effects on albumin or creatinine stability were noted in appropriately supervised patients. The study concludes that Ramadan fasting can be safe for stable CKD and ESRD patients with careful monitoring, dietary management, and individualized medical supervision to mitigate metabolic fluctuations.
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 719-737
Open AccessEffect of Ramadan Fasting on Chronic Kidney Disease Patients
This prospective cohort study evaluated the impact of Ramadan fasting on 162 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) on regular hemodialysis. Participants were categorized based on fasting behavior and renal status. Biochemical and clinical parameters were assessed before, during, and after Ramadan. Results indicated that fasting was generally well-tolerated, though significant transient increases in blood urea, potassium, and phosphate were observed during fasting periods, particularly among ESRD patients fasting on dialysis days. Serum sodium and eGFR showed significant declines over time in both fasting and non-fasting CKD groups. No adverse effects on albumin or creatinine stability were noted in appropriately supervised patients. The study concludes that Ramadan fasting can be safe for stable CKD and ESRD patients with careful monitoring, dietary management, and individualized medical supervision to mitigate metabolic fluctuations.
- Open Access
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2751
Correlation of Vitamin D Level with Body Physique and Glycemic Control in Type1 Diabetic Egyptian Children and Adolescents
Vitamin D is increasingly recognized for its immunomodulatory and metabolic effects, with growing evidence linking deficiency to the development and progression of type 1 diabetes mellitus (T1DM).We aimed To evaluate vitamin D status among Egyptian T1D pediatric patients and explore its relationship with glycemic control and body physique. A cross-sectional study was conducted on pediatric patients with T1DM. Serum 25-hydroxyvitamin D [25(OH)D] levels were assessed and categorized as deficient, insufficient, or sufficient. Clinical, anthropometric and biochemical parameters, including glycated hemoglobin (HbA1c), were assessed to determine associations with vitamin D status. Body composition was also analyzed. Vitamin D deficiency was highly prevalent, with the majority of patients demonstrating either deficient or insufficient levels. Lower VD levels were significantly associated with poorer glycemic control and higher BMI and body fat. There was no direct correlation between VD and HbA1c. We concluded that Vitamin D deficiency is common in Egyptian diabetic pediatric patients and is associated with adverse glycemic outcomes and higher BMI and body fat. Routine screening and appropriate supplementation may represent a valuable adjunct in disease management, although further future researches are required to confirm causality and establish evidence-based supplementation strategies.
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2751
Open AccessCorrelation of Vitamin D Level with Body Physique and Glycemic Control in Type1 Diabetic Egyptian Children and Adolescents
Vitamin D is increasingly recognized for its immunomodulatory and metabolic effects, with growing evidence linking deficiency to the development and progression of type 1 diabetes mellitus (T1DM).We aimed To evaluate vitamin D status among Egyptian T1D pediatric patients and explore its relationship with glycemic control and body physique. A cross-sectional study was conducted on pediatric patients with T1DM. Serum 25-hydroxyvitamin D [25(OH)D] levels were assessed and categorized as deficient, insufficient, or sufficient. Clinical, anthropometric and biochemical parameters, including glycated hemoglobin (HbA1c), were assessed to determine associations with vitamin D status. Body composition was also analyzed. Vitamin D deficiency was highly prevalent, with the majority of patients demonstrating either deficient or insufficient levels. Lower VD levels were significantly associated with poorer glycemic control and higher BMI and body fat. There was no direct correlation between VD and HbA1c. We concluded that Vitamin D deficiency is common in Egyptian diabetic pediatric patients and is associated with adverse glycemic outcomes and higher BMI and body fat. Routine screening and appropriate supplementation may represent a valuable adjunct in disease management, although further future researches are required to confirm causality and establish evidence-based supplementation strategies.
- Open Access
- 12 December 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
HSP-70 and TNF-α as predictors of acute respiratory distress syndrome in children with pneumonia
Community acquired pneumonia is a leading cause of pediatric hospitalization worldwide. Identifying predictor for pneumonia severity and complications is critical to improve the diagnosis and outcome. This study aimed to evaluate the role Heat shock protein-70 (HSP-70) and Tumor necrosis factor alpha (TNF-α) as predictors of acute respiratory distress syndrome (ARDS) in children with pneumonia. The current cross sectional study included 60 child with pneumonia who were referred for admission in pediatric intensive care during the period from February 2024 to July 2024. Clinical data, HSP-70, TNF-α serum levels, isolated bacteria and bacterial biofilm formation were assessed in all children. We found that 15 out of 60 included children developed ARDS (25%). Heat shock protein-70 and TNF-α were statistically significant higher in those who developed ARDS than those without ARDS. Isolated bacteria and a higher rate of biofilm formation were substantially higher in patients who developed ARDS. HSP-70 had 93.3% sensitivity and 91.1% specificity at cutoff point of 5.5 ng/ml and TNF-α had 93.3% sensitivity and 86.7% specificity at a cutoff point of 442 pg/ml to predict ARDS in children with pneumonia. Elevated HSP-70 (OR:10.5) elevated TNF- α (OR: 6), bacterial biofilm formation (OR:7.3), respiratory acidosis (OR:6), and low PaO2/FiO2 < 300 (OR:1.667) were independent predictors for development of ARDS. In conclusion, several confounders contribute to the development of ARDS in children with pneumonia included inflammatory biomarkers, bacterial biofilm formation, respiratory acidosis, and reduced PaO₂/FiO₂ ratios. HSP-70 and TNF-α showed good predictive performance, indicating their potential utility as early biomarkers for identifying high-risk patients.
- 12 December 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Open AccessHSP-70 and TNF-α as predictors of acute respiratory distress syndrome in children with pneumonia
Community acquired pneumonia is a leading cause of pediatric hospitalization worldwide. Identifying predictor for pneumonia severity and complications is critical to improve the diagnosis and outcome. This study aimed to evaluate the role Heat shock protein-70 (HSP-70) and Tumor necrosis factor alpha (TNF-α) as predictors of acute respiratory distress syndrome (ARDS) in children with pneumonia. The current cross sectional study included 60 child with pneumonia who were referred for admission in pediatric intensive care during the period from February 2024 to July 2024. Clinical data, HSP-70, TNF-α serum levels, isolated bacteria and bacterial biofilm formation were assessed in all children. We found that 15 out of 60 included children developed ARDS (25%). Heat shock protein-70 and TNF-α were statistically significant higher in those who developed ARDS than those without ARDS. Isolated bacteria and a higher rate of biofilm formation were substantially higher in patients who developed ARDS. HSP-70 had 93.3% sensitivity and 91.1% specificity at cutoff point of 5.5 ng/ml and TNF-α had 93.3% sensitivity and 86.7% specificity at a cutoff point of 442 pg/ml to predict ARDS in children with pneumonia. Elevated HSP-70 (OR:10.5) elevated TNF- α (OR: 6), bacterial biofilm formation (OR:7.3), respiratory acidosis (OR:6), and low PaO2/FiO2 < 300 (OR:1.667) were independent predictors for development of ARDS. In conclusion, several confounders contribute to the development of ARDS in children with pneumonia included inflammatory biomarkers, bacterial biofilm formation, respiratory acidosis, and reduced PaO₂/FiO₂ ratios. HSP-70 and TNF-α showed good predictive performance, indicating their potential utility as early biomarkers for identifying high-risk patients.
- Open Access
- 28 October 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (2) , 349-356
Serum TNF-α, oxidized LDL, and APOCII as novel predictors for familial mediterranean fever in Egyptian children: a cross-sectional study
Persistent subclinical inflammation is a hallmark of familial Mediterranean fever (FMF), the most common autoinflammatory disease. Among the key mediators implicated in this chronic inflammatory state are tumor necrosis factor-alpha (TNF-α), oxidized low-density lipoprotein (OxLDL), and apolipoprotein C-II (APOC2), which contribute to the dysregulated immune response characteristic of FMF. The present study aims to evaluate the potential role of TNF-α, OxLDL, and APOC2 as diagnostic biomarkers of disease severity in patients with FMF. Methods: The study enrolled 66 patients diagnosed with FMF and 60 age- and gender-matched healthy controls. Serum levels of tumor necrosis factor-alpha (TNF-α) and oxidized low-density lipoprotein (OxLDL) were quantified using the enzyme-linked immunosorbent assay (ELISA) technique. However, the apolipoprotein C-II (APOC2) concentrations were measured using an automated biochemistry analyzer. Furthermore, the Carotid intima media was assessed. Results: Serum TNF-α levels were significantly higher in FMF patients than in the control group, emphasizing the protein’s role as an important marker of chronic inflammation. Levels of low-density lipoprotein (OxLDL) and apolipoprotein C-II (APOC2) were also notably altered in the FMF cohort. Notably, OxLDL, APOC2 and TNF-α demonstrated strong positive correlation with attack frequency, multiple linear regressions analysis showed that OxLDL (β=1.53, p=0.002) and TNF-α (β=1.38, p=0.003) were significant predictors for higher number of attacks, suggesting their potential role involvement in the inflammatory cascade and their utility as complementary biomarkers in FMF. The carotid intima-media thickness (CIMT) of patients and control subjects did not differ statistically significantly. Conclusions: TNF-α, oxidized LDL, and APOC2 are key pro-inflammatory mediators that may serve as novel biomarkers for assessing chronic inflammatory status in FMF patients. Their elevated levels could provide valuable insights into disease progression and help guide personalized treatment strategies.
- 28 October 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (2) , 349-356
Open AccessSerum TNF-α, oxidized LDL, and APOCII as novel predictors for familial mediterranean fever in Egyptian children: a cross-sectional study
Persistent subclinical inflammation is a hallmark of familial Mediterranean fever (FMF), the most common autoinflammatory disease. Among the key mediators implicated in this chronic inflammatory state are tumor necrosis factor-alpha (TNF-α), oxidized low-density lipoprotein (OxLDL), and apolipoprotein C-II (APOC2), which contribute to the dysregulated immune response characteristic of FMF. The present study aims to evaluate the potential role of TNF-α, OxLDL, and APOC2 as diagnostic biomarkers of disease severity in patients with FMF. Methods: The study enrolled 66 patients diagnosed with FMF and 60 age- and gender-matched healthy controls. Serum levels of tumor necrosis factor-alpha (TNF-α) and oxidized low-density lipoprotein (OxLDL) were quantified using the enzyme-linked immunosorbent assay (ELISA) technique. However, the apolipoprotein C-II (APOC2) concentrations were measured using an automated biochemistry analyzer. Furthermore, the Carotid intima media was assessed. Results: Serum TNF-α levels were significantly higher in FMF patients than in the control group, emphasizing the protein’s role as an important marker of chronic inflammation. Levels of low-density lipoprotein (OxLDL) and apolipoprotein C-II (APOC2) were also notably altered in the FMF cohort. Notably, OxLDL, APOC2 and TNF-α demonstrated strong positive correlation with attack frequency, multiple linear regressions analysis showed that OxLDL (β=1.53, p=0.002) and TNF-α (β=1.38, p=0.003) were significant predictors for higher number of attacks, suggesting their potential role involvement in the inflammatory cascade and their utility as complementary biomarkers in FMF. The carotid intima-media thickness (CIMT) of patients and control subjects did not differ statistically significantly. Conclusions: TNF-α, oxidized LDL, and APOC2 are key pro-inflammatory mediators that may serve as novel biomarkers for assessing chronic inflammatory status in FMF patients. Their elevated levels could provide valuable insights into disease progression and help guide personalized treatment strategies.
- Open Access
- 28 October 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (2) , 328-340
Impact of the nitric oxide substrate L-arginine alone and combined with atropine on malathion neuro and hepato-toxicity
Objectives: We investigated the impact of the nitric oxide substrate L-arginine on the neuro- and hepato-toxic effects of malathion in rats. Methods: Rats were treated intraperitoneally with malathion (150 mg/kg) alone or combined with L-arginine (100, 200 or 400 mg/kg), atropine (2 mg/kg) or L-arginine (200 mg/kg) combined with atropine (2 mg/kg). Rats were euthanized 4 h later, and their brains and livers analyzed for malondialdehyde, nitric oxide (NO), reduced glutathione (GSH), paraoxonase-1 (PON-1). Moreover, butyrylcholinesterase (BChE), interleukin-15 (IL-15) and anti-apoptotic protein B cell/lymphoma-2 (Bcl-2) were determined in brain tissue. Histopatholoy was also performed. Results: Malathion significantly raised brain NO and malondialdehyde alongside with a notable drop in PON-1 activity and GSH levels relative to the saline control. Brain BChE and Bcl-2 were markedly inhibited whereas IL-15 significantly increased by malathion. In brain, L-arginine treatment resulted in a significantly increased malondialdehyde, decreased GSH, and increased IL-15. A significant decrease in liver malondialdehyde occurred by L-arginine/atropine or atropine. In contrast, L-arginine, L-arginine/atropine or atropine caused a significant decrease in brain and liver NO levels and increased PON-1 activity. Bcl-2 in brain significantly increased by atropine. Malathion induced brain neuronal and liver degeneration showed marked improvement after atropine alone. Conclusions: These results indicated that exogenously administered L-arginine did not protect against the neuro- and hepto-toxic effects of malathion. Meanwhile, the ability of atropine to mitigate the deleterious effects of a toxic dose of malathion provides a strong support to the role of excessive stimulation cholinergic pathways in inflicting such damage.
- 28 October 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (2) , 328-340
Open AccessImpact of the nitric oxide substrate L-arginine alone and combined with atropine on malathion neuro and hepato-toxicity
Objectives: We investigated the impact of the nitric oxide substrate L-arginine on the neuro- and hepato-toxic effects of malathion in rats. Methods: Rats were treated intraperitoneally with malathion (150 mg/kg) alone or combined with L-arginine (100, 200 or 400 mg/kg), atropine (2 mg/kg) or L-arginine (200 mg/kg) combined with atropine (2 mg/kg). Rats were euthanized 4 h later, and their brains and livers analyzed for malondialdehyde, nitric oxide (NO), reduced glutathione (GSH), paraoxonase-1 (PON-1). Moreover, butyrylcholinesterase (BChE), interleukin-15 (IL-15) and anti-apoptotic protein B cell/lymphoma-2 (Bcl-2) were determined in brain tissue. Histopatholoy was also performed. Results: Malathion significantly raised brain NO and malondialdehyde alongside with a notable drop in PON-1 activity and GSH levels relative to the saline control. Brain BChE and Bcl-2 were markedly inhibited whereas IL-15 significantly increased by malathion. In brain, L-arginine treatment resulted in a significantly increased malondialdehyde, decreased GSH, and increased IL-15. A significant decrease in liver malondialdehyde occurred by L-arginine/atropine or atropine. In contrast, L-arginine, L-arginine/atropine or atropine caused a significant decrease in brain and liver NO levels and increased PON-1 activity. Bcl-2 in brain significantly increased by atropine. Malathion induced brain neuronal and liver degeneration showed marked improvement after atropine alone. Conclusions: These results indicated that exogenously administered L-arginine did not protect against the neuro- and hepto-toxic effects of malathion. Meanwhile, the ability of atropine to mitigate the deleterious effects of a toxic dose of malathion provides a strong support to the role of excessive stimulation cholinergic pathways in inflicting such damage.
- Open Access
- 30 September 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (3) , 1947-1952
Fecal Calprotectin and CRP: Noninvasive Biomarkers in IBD
Inflammatory bowel disease (IBD) is a chronic, relapsing-remitting condition of the gastrointestinal tract with an unclear etiology. It is characterized by alternating periods of active inflammation and clinical remission. Among the biomarkers used to assess disease activity, serum C-reactive protein (CRP) and fecal calprotectin (FCP) have emerged as noninvasive, reliable indicators of intestinal inflammation, offering valuable insights into disease monitoring and management. A total of 150 patients with IBD, and 150 control subjects with no history of intestinal resections were included and were prospectively recruited from the IBD Clinic of the National Institute of Hepatology and Tropical Medicine (NHTMRI) and the Clinical Genetics Department of the National Research Centre. (FCP) and (CRP) markers were measured. Receiver operating characteristic (ROC) curves were used to evaluate the accuracy of FCP and CRP for diagnosing inflammatory activity. The median values of these markers were significantly higher in IBD than in controls. FC was associated with higher sensitivity than CRP for the diagnosis of IBD. ROC curve analysis revealed FCP had higher sensitivity for diagnosing with a higher area under the curve than CRP. We concluded that both (CRP) and (FCP) demonstrated a strong association with colorectal inflammation. These biomarkers can serve as valuable tools for monitoring treatment response, screening asymptomatic individuals, and predicting disease relapse in patients with inflammatory bowel disease (IBD).
- 30 September 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (3) , 1947-1952
Open AccessFecal Calprotectin and CRP: Noninvasive Biomarkers in IBD
Inflammatory bowel disease (IBD) is a chronic, relapsing-remitting condition of the gastrointestinal tract with an unclear etiology. It is characterized by alternating periods of active inflammation and clinical remission. Among the biomarkers used to assess disease activity, serum C-reactive protein (CRP) and fecal calprotectin (FCP) have emerged as noninvasive, reliable indicators of intestinal inflammation, offering valuable insights into disease monitoring and management. A total of 150 patients with IBD, and 150 control subjects with no history of intestinal resections were included and were prospectively recruited from the IBD Clinic of the National Institute of Hepatology and Tropical Medicine (NHTMRI) and the Clinical Genetics Department of the National Research Centre. (FCP) and (CRP) markers were measured. Receiver operating characteristic (ROC) curves were used to evaluate the accuracy of FCP and CRP for diagnosing inflammatory activity. The median values of these markers were significantly higher in IBD than in controls. FC was associated with higher sensitivity than CRP for the diagnosis of IBD. ROC curve analysis revealed FCP had higher sensitivity for diagnosing with a higher area under the curve than CRP. We concluded that both (CRP) and (FCP) demonstrated a strong association with colorectal inflammation. These biomarkers can serve as valuable tools for monitoring treatment response, screening asymptomatic individuals, and predicting disease relapse in patients with inflammatory bowel disease (IBD).
- Open Access
- 24 January 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-5
The role of cyclooxygenase-2 (COX-2) and inflammatory markers in the progress of Alport syndrome in Egyptian children
Background: Chronic inflammation and its control are crucial to the responses of glomerular and renal tubular cells. This contributes to the pathogenic mechanisms and advancement of the disease in Alport syndrome. The study aimed to elucidate the role of cyclooxygenase-2, Interleukin 4, Plasminogen activating inhibitor 1, and Prostaglandin E2 in the development and course of Alport syndrome. Methods: In our study inflammatory markers were evaluated in 26 Alport syndrome patients, 15 males and 11 females and 24 controls. Results: Their age ranged from 4 to 16 years (mean ± SD was 8.50 ± 2.877) and 24 were normal controls matching age and sex. The serum levels of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were evaluated in all patients. The serum level of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were all increased significantly in the Alport syndrome patients compared to control (588.68 ± 73.08, 42.57 ± 4.18, 42.32 ± 3.49, and 846.47 ± 45.433, respectively versus controls (369.12 ± 50.28, 25.52 ± 4.98, 28.89 ± 3.19, and 312.79 ± 40.53 respectively). Conclusion: The role of inflammatory markers cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 in Alport syndrome that are causally connected and have a role in the development and course of Alport disease was delineated. This may highlight and speculate an innovative strategy for targeting the creation of safe and efficient anti-inflammatory treatments to inhibit disease progression in Alport syndrome.
- 24 January 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-5
Open AccessThe role of cyclooxygenase-2 (COX-2) and inflammatory markers in the progress of Alport syndrome in Egyptian children
Background: Chronic inflammation and its control are crucial to the responses of glomerular and renal tubular cells. This contributes to the pathogenic mechanisms and advancement of the disease in Alport syndrome. The study aimed to elucidate the role of cyclooxygenase-2, Interleukin 4, Plasminogen activating inhibitor 1, and Prostaglandin E2 in the development and course of Alport syndrome. Methods: In our study inflammatory markers were evaluated in 26 Alport syndrome patients, 15 males and 11 females and 24 controls. Results: Their age ranged from 4 to 16 years (mean ± SD was 8.50 ± 2.877) and 24 were normal controls matching age and sex. The serum levels of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were evaluated in all patients. The serum level of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were all increased significantly in the Alport syndrome patients compared to control (588.68 ± 73.08, 42.57 ± 4.18, 42.32 ± 3.49, and 846.47 ± 45.433, respectively versus controls (369.12 ± 50.28, 25.52 ± 4.98, 28.89 ± 3.19, and 312.79 ± 40.53 respectively). Conclusion: The role of inflammatory markers cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 in Alport syndrome that are causally connected and have a role in the development and course of Alport disease was delineated. This may highlight and speculate an innovative strategy for targeting the creation of safe and efficient anti-inflammatory treatments to inhibit disease progression in Alport syndrome.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 22 (2) , 279-287
Effect of amifostine on apoptotic inflammatory makers in cisplatin induced brain damage in rats
Objectives: To lessen the negative effects of the medication, we assessed the neuroprotective impact of amifostine nanoparticles against the neurotoxicity generated by cisplatin. Methods: 60 adult male albino Wistar rats were arranged into six groups. Group 1; received saline intraperitonealy (IP) and served as negative control. Group 2; received IP injection of silica nano-emulsion, Group 3 received cispatin for three consecutive days at the end of the study, Group 4 received amifostine intrapretonealy (IP) before cisplatin injection, Group 5 received silica nano-emulsion alone for one month, group 6 received silica nano-emulsion in combination with cisplatin for three consecutive days at the end of the study. Monocyte chemoattractant protein-1 (MCP-1) and glial fibrillary acidic protein (GFAP) were estimated by ELISA, butrylcholinesterase (BChE) by spectrophotometric method while caspase-3 as a marker of apoptosis by PCR. Results: The mean levels of brain GFAP, MCP-1, and caspase-3 in the cisplatin group were considerably higher than those in the control group. However, there was a drop in the average level of brain BChE activity. Additionally, the injection of (SiNPs@AMF + cisplatin) increased BChE activities while reducing GFAP, MCP-1, and caspase-3 levels, thereby reversing the negative effects of cisplatin on the brain tissue. On the other hand, the group treated with SiNPs@AMF + cisplatin showed improvement in overall brain structure and minimal pyknotic nuclei and apoptotic neurons were found. Conclusions: These outcomes demonstrated amifostine’s ability to lessen the histological changes brought on by cisplatin. To sum up, SiNPs@AMF may be a suitable and secure supplemental treatment agent to lessen cisplatin’s toxicity in the brain and enhance the treatment’s effects throughout chemotherapy.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 22 (2) , 279-287
Effect of amifostine on apoptotic inflammatory makers in cisplatin induced brain damage in rats
Objectives: To lessen the negative effects of the medication, we assessed the neuroprotective impact of amifostine nanoparticles against the neurotoxicity generated by cisplatin. Methods: 60 adult male albino Wistar rats were arranged into six groups. Group 1; received saline intraperitonealy (IP) and served as negative control. Group 2; received IP injection of silica nano-emulsion, Group 3 received cispatin for three consecutive days at the end of the study, Group 4 received amifostine intrapretonealy (IP) before cisplatin injection, Group 5 received silica nano-emulsion alone for one month, group 6 received silica nano-emulsion in combination with cisplatin for three consecutive days at the end of the study. Monocyte chemoattractant protein-1 (MCP-1) and glial fibrillary acidic protein (GFAP) were estimated by ELISA, butrylcholinesterase (BChE) by spectrophotometric method while caspase-3 as a marker of apoptosis by PCR. Results: The mean levels of brain GFAP, MCP-1, and caspase-3 in the cisplatin group were considerably higher than those in the control group. However, there was a drop in the average level of brain BChE activity. Additionally, the injection of (SiNPs@AMF + cisplatin) increased BChE activities while reducing GFAP, MCP-1, and caspase-3 levels, thereby reversing the negative effects of cisplatin on the brain tissue. On the other hand, the group treated with SiNPs@AMF + cisplatin showed improvement in overall brain structure and minimal pyknotic nuclei and apoptotic neurons were found. Conclusions: These outcomes demonstrated amifostine’s ability to lessen the histological changes brought on by cisplatin. To sum up, SiNPs@AMF may be a suitable and secure supplemental treatment agent to lessen cisplatin’s toxicity in the brain and enhance the treatment’s effects throughout chemotherapy.